{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:32:19Z","timestamp":1772692339237,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2010\/51417-0"],"award-info":[{"award-number":["2010\/51417-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Environ Biophys"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00411-016-0646-5","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T11:51:53Z","timestamp":1458820313000},"page":"317-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cytogenetic and dosimetric effects of 131I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments"],"prefix":"10.1007","volume":"55","author":[{"given":"M\u00e1rcia Augusta","family":"da Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via Gomes Silva","family":"Valg\u00f4de","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia Armiliato","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9lio","family":"Yoriyaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria In\u00eas Calil Cury","family":"Guimar\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa Carvalho Pinto","family":"Ribela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Buchpiguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bartolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"646_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1383-5718(01)00323-0","volume":"514","author":"M Ballardin","year":"2002","unstructured":"Ballardin M, Gemignani F, Bodei L, Mariani G, Ferdeghini M, Rossi AM, Migliore L, Barale R (2002) Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res 514:77\u201385","journal-title":"Mutat Res"},{"key":"646_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2307\/3579122","volume":"140","author":"L Baugnet-Mahieu","year":"1994","unstructured":"Baugnet-Mahieu L, Lemaire M, L\u00e9onard ED, L\u00e9onard A, Gerber GB (1994) Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. Radiat Res 140:429\u2013431","journal-title":"Radiat Res"},{"key":"646_CR3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00259-008-0754-9","volume":"35","author":"I Borget","year":"2008","unstructured":"Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, De Pouvourville G (2008) Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients:comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 35:1457\u20131463","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"646_CR4","unstructured":"Briemeister JF (2000) MCNP: a general Monte Carlo N-particle transport code. Los Alamos Scientific Laboratory (LA-13709-M, Ver.4C)"},{"key":"646_CR5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3892\/ol.2011.523","volume":"3","author":"MR Carvalho","year":"2012","unstructured":"Carvalho MR, Ferreira TC, Leite V (2012) Evaluation of whole-body retention of iodine-131(131I) after postoperative remnant ablation for differentiated thyroid carcinoma- thyroxine withdrawal versus rhTSH administration: a retrospective comparison. Oncol Lett 3:617\u2013620","journal-title":"Oncol Lett"},{"key":"646_CR6","first-page":"1522","volume":"41","author":"C Catena","year":"2000","unstructured":"Catena C, Conti D, Trenta G, Righi E, Breuer F, Melacrinis FF, Montesano T, Ventroni G, Ronga G (2000) Micronucleus yield and colorimetric test as indicators of damage in patients\u2019 lymphocytes after 131I therapy. J Nucl Med 41:1522\u20131524","journal-title":"J Nucl Med"},{"key":"646_CR7","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1002\/cncr.24416","volume":"15","author":"AY Chen","year":"2009","unstructured":"Chen AY, Jemal A, Ward EM (2009) Increasing incidence of differentiated thyroid cancer in the United States, 1988\u20132005. Cancer 15:3801\u20133807","journal-title":"Cancer"},{"key":"646_CR8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/nbt0993-1014","volume":"11","author":"ES Cole","year":"1993","unstructured":"Cole ES, Lee K, Lauziere K, Kelton C, Chappel S, Weintraub B, Ferrara D, Peterson B, Bernasconi R, Edmunds T et al (1993) Recombinant human thyroid stimulating hormone: development of a biotechnology product for detection of metastatic lesions of thyroid carcinoma. Bio\/Technology 11:1014\u20131024","journal-title":"Bio\/Technology"},{"key":"646_CR9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00411-008-0189-5","volume":"47","author":"MA Silva da","year":"2008","unstructured":"da Silva MA, Guimar\u00e3es MICC, Yoriyaz H, Ribela MTCP, Buchpiguel CA, Bartolini P, Okazaki K (2008) Evaluation of the cytogenetic effects of 131I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats. Radiat Environ Biophys 47:453\u2013461","journal-title":"Radiat Environ Biophys"},{"key":"646_CR10","first-page":"1549","volume":"45","author":"B Keizer de","year":"2004","unstructured":"de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJM, de Klerk JMH (2004) Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 45:1549\u20131554","journal-title":"J Nucl Med"},{"key":"646_CR11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00259-003-1427-3","volume":"31","author":"T Erselcan","year":"2004","unstructured":"Erselcan T, Sungu S, Ozdemir S, Turgut B, Dogan D, Ozdemir O (2004) Iodine-131 treatment and chromosomal damage: in vivo dose\u2013effect relationship. Eur J Nucl Med Mol Imaging 31:676\u2013684","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"646_CR12","first-page":"17N","volume":"42","author":"LE Feinendegen","year":"2001","unstructured":"Feinendegen LE, Pollycove M (2001) Biologic responses to low doses of ionizing radiation: detriment versus hormesis. J Nucl Med 42:17N\u201327N","journal-title":"J Nucl Med"},{"key":"646_CR13","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1210\/jc.2008-2830","volume":"94","author":"A Frigo","year":"2009","unstructured":"Frigo A, Dardano A, Danese E, Dav\u00ec MV, Moghetti P, Colato C, Francia G, Bernardi F, Traino C, Monzani F et al (2009) Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 94:3472\u20133476","journal-title":"J Clin Endocrinol Metab"},{"key":"646_CR14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/mutage\/15.1.69","volume":"15","author":"OM Gil","year":"2000","unstructured":"Gil OM, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, L\u00e9onard A, Gerber G, Rueffl J (2000) Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 15:69\u201375","journal-title":"Mutagenesis"},{"key":"646_CR15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0165-1161(96)00005-2","volume":"360","author":"S Gundy","year":"1996","unstructured":"Gundy S, Katz N, Fuzy M, \u00c9sik O (1996) Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodine. Mutat Res 360:107\u2013113","journal-title":"Mutat Res"},{"key":"646_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1383-5718(98)00010-2","volume":"413","author":"S Guti\u00e9rrez","year":"1998","unstructured":"Guti\u00e9rrez S, Carbonell E, Galofr\u00e9 P, Creus A, Marcos R (1998) The alkaline single-cell gel electrophoresis (SCGE) assay applied to the analysis of radiation-induced DNA damage in thyroid cancer patients treated with 131I. Mutat Res 413:111\u2013119","journal-title":"Mutat Res"},{"key":"646_CR17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s002590050499","volume":"26","author":"A Guti\u00e9rrez","year":"1999","unstructured":"Guti\u00e9rrez A, Carbonelli E, Galofr\u00e9 P, Creus A, Marcos R (1999) Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. Eur J Nucl Med 26:1589\u20131596","journal-title":"Eur J Nucl Med"},{"key":"646_CR18","volume-title":"Radiobiology for the radiologist","author":"EJ Hall","year":"2000","unstructured":"Hall EJ (2000) Radiobiology for the radiologist, 5th edn. Lippincott Williams, New York","edition":"5"},{"key":"646_CR19","first-page":"648","volume":"47","author":"H H\u00e4nscheid","year":"2006","unstructured":"H\u00e4nscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M et al (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648\u2013654","journal-title":"J Nucl Med"},{"key":"646_CR20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1677\/ERC-09-0076","volume":"16","author":"H H\u00e4nscheid","year":"2009","unstructured":"H\u00e4nscheid H, Lassmann M, Luster M, Kloos RT, Reiners C (2009) Blood dosimetry from a single measurements of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 16:1283\u20131289","journal-title":"Endocr Relat Cancer"},{"key":"646_CR21","volume-title":"Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies","author":"International Atomic Energy Agency","year":"2011","unstructured":"International Atomic Energy Agency (2011) Cytogenetic dosimetry: applications in preparedness for and response to radiation emergencies. Scientific and Technical Publications, Vienna"},{"key":"646_CR22","doi-asserted-by":"crossref","unstructured":"International Commission on Radiological protection (ICRP) (2012) Tissue reactions\/early and late effects of radiation in normal tissues and organs: threshold doses for tissue reactions in a radiation protection context. ICRP Publication 118. Ann. ICRP 41 (1\/2)","DOI":"10.1016\/j.icrp.2012.02.001"},{"key":"646_CR23","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1503\/cmaj.061730","volume":"177","author":"WDT Kent","year":"2007","unstructured":"Kent WDT, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA (2007) Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177:1357\u20131361","journal-title":"CMAJ"},{"key":"646_CR24","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","volume":"35","author":"M Lassmann","year":"2008","unstructured":"Lassmann M, H\u00e4nscheid H, Chiesa C, Hindorf C, Flux G, Luster M (2008) EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry. I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Mol Imaging 35:1405\u20131412","journal-title":"Eur J Nucl Mol Imaging"},{"key":"646_CR25","doi-asserted-by":"crossref","first-page":"R161","DOI":"10.1677\/ERC-10-0071","volume":"17","author":"M Lassmann","year":"2010","unstructured":"Lassmann M, Reiners C, Luster M (2010) Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 17:R161\u2013R172","journal-title":"Endocr Relat Cancer"},{"key":"646_CR01","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/02841860600979013","volume":"45","author":"M Luster","year":"2006","unstructured":"Luster M (2006) Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncol 45:1018\u20131030","journal-title":"Acta Oncol"},{"key":"646_CR26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1677\/erc.1.00830","volume":"12","author":"M Luster","year":"2005","unstructured":"Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F (2005) RhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49\u201364","journal-title":"Endocr Relat Cancer"},{"key":"646_CR27","first-page":"1860","volume":"37","author":"R M\u2019Kacher","year":"1996","unstructured":"M\u2019Kacher R, Legal JD, Schlumberger M, Voisin P, Aubert B, Gaillard N, Parmentier C (1996) Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. J Nucl Med 37:1860\u20131864","journal-title":"J Nucl Med"},{"key":"646_CR28","first-page":"377","volume":"38","author":"R M\u2019Kacher","year":"1997","unstructured":"M\u2019Kacher R, L\u00e9gal JD, Schlumberger M, Aubert B, Gaillard N, Gaussen A, Parmentier C (1997) Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma. J Nucl Med 38:377\u2013380","journal-title":"J Nucl Med"},{"key":"646_CR29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chroma.2004.10.084","volume":"1062","author":"F Mendon\u00e7a","year":"2005","unstructured":"Mendon\u00e7a F, Oliveira JE, Bartolini P, Ribela MTCP (2005) Two-step chromatographic purification of recombinant human thyrotrophin and its immunological, biological, physico-chemical and mass spectral characterization. J Chromatogr A 1062:103\u2013112","journal-title":"J Chromatogr A"},{"key":"646_CR30","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00006231-199910000-00008","volume":"10","author":"MA Monsieurs","year":"1999","unstructured":"Monsieurs MA, Thierens HM, van de Wiele CV, Vral AM, Meirlaen IA, de Winter HA, de Sadeleer CJ, de Ridder LI, Kaufman JM, Dierckx RA (1999) Estimation of risk based on biological dosimetry for patients treated with radioiodine. Nucl Med Commun 10:911\u2013917","journal-title":"Nucl Med Commun"},{"key":"646_CR31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.beem.2008.09.014","volume":"22","author":"F Pacini","year":"2008","unstructured":"Pacini F, Castagna MG (2008) Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 22:1009\u20131021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"646_CR32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/rpd\/nct285","volume":"162","author":"M Pinto","year":"2014","unstructured":"Pinto M, Amaral A (2014) Biological dose assessment after low-dose overexposures in nuclear medicine. Radiat Prot Dosim 162:254\u2013259","journal-title":"Radiat Prot Dosim"},{"key":"646_CR33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/mutage\/12.6.449","volume":"12","author":"MJ Ramirez","year":"1997","unstructured":"Ramirez MJ, Surrall\u00e9s J, Galofr\u00e9 P, Creus A, Marcos R (1997) Radioactive iodine induces clastogenic and age-dependent aneugenic effects in lymphocytes of thyroid cancer patients as revealed by interphase FISH. Mutagenesis 12:449\u2013455","journal-title":"Mutagenesis"},{"key":"646_CR34","first-page":"30","volume":"35","author":"C Reiners","year":"2012","unstructured":"Reiners C, Lassmann M, Luster M (2012) Recombinant human thyrotropin: safety and quality of life evaluation. J Endocrinol Invest 35:30\u201335","journal-title":"J Endocrinol Invest"},{"key":"646_CR35","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2967\/jnumed.108.052464","volume":"49","author":"H Remy","year":"2008","unstructured":"Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J, Bournaud C, Gupta S, Schlumberger M, Ricard M (2008) 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445\u20131450","journal-title":"J Nucl Med"},{"key":"646_CR36","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.2967\/jnumed.108.050591","volume":"49","author":"PW Ros\u00e1rio","year":"2008","unstructured":"Ros\u00e1rio PW, Borges MAR, Purisch S (2008) Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776\u20131782","journal-title":"J Nucl Med"},{"key":"646_CR37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/rpd\/ncm444","volume":"129","author":"A Serna","year":"2008","unstructured":"Serna A, Alcaraz M, Navarro JL, Acevedo C, Vicente V, Canteras M (2008) Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients. Radiat Prot Dosim 129:372\u2013380","journal-title":"Radiat Prot Dosim"},{"key":"646_CR38","first-page":"898","volume":"44","author":"JC Sisson","year":"2003","unstructured":"Sisson JC, Shulkin BL, Lawson S (2003) Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retention of 131I. J Nucl Med 44:898\u2013903","journal-title":"J Nucl Med"},{"key":"646_CR39","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1210\/jc.2009-2528","volume":"95","author":"D Ta\u00efeb","year":"2010","unstructured":"Ta\u00efeb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, Bourrelly M, Mancini J, De Micco C, Auquier P et al (2010) Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 95:3283\u20133290","journal-title":"J Clin Endocrinol Metab"},{"key":"646_CR02","first-page":"436","volume":"39","author":"N Watanabe","year":"1998","unstructured":"Watanabe N, Yokoyama K, Kinuya S, Shuke N, Shimizu M, Futatsuya R, Michigishi T, Tonami N, Seto H, Goodwin DA (1998) Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay. J Nucl Med 39:436\u2013440","journal-title":"J Nucl Med"},{"key":"646_CR40","first-page":"608","volume":"45","author":"N Watanabe","year":"2004","unstructured":"Watanabe N, Kanegane H, Kinuya S, Shuke N, Yokoyama K, Kato H, Tomizawa G, Shimizu M, Funada H, Seto H (2004) The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med 45:608\u2013611","journal-title":"J Nucl Med"},{"key":"646_CR41","first-page":"53","volume":"33","author":"P Zanotti-Fregonara","year":"2008","unstructured":"Zanotti-Fregonara P, Toubert ME, Ta\u00efeb D, Ravasi L, Rubello D, Hindie E (2008) Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin. Minerva Endocrinol 33:53\u201365","journal-title":"Minerva Endocrinol"},{"key":"646_CR42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/thy.1997.7.199","volume":"7","author":"PB Zanzonico","year":"1997","unstructured":"Zanzonico PB (1997) Radiation dose to patients and relatives incident to 131I therapy. Thyroid 7:199\u2013204","journal-title":"Thyroid"}],"container-title":["Radiation and Environmental Biophysics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00411-016-0646-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00411-016-0646-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00411-016-0646-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T19:35:29Z","timestamp":1567712129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00411-016-0646-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["646"],"URL":"https:\/\/doi.org\/10.1007\/s00411-016-0646-5","relation":{},"ISSN":["0301-634X","1432-2099"],"issn-type":[{"value":"0301-634X","type":"print"},{"value":"1432-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]}}}